Longevity & AgingPress Release

Same-Day COVID and Flu Shots Pose No Extra Risk, Large Study Confirms

A VA study of 2.5 million people finds coadministering COVID and flu vaccines on the same day is as safe as getting a flu shot alone.

Tuesday, June 30, 2026 2 views
Published in MedPage Today
Article visualization: Same-Day COVID and Flu Shots Pose No Extra Risk, Large Study Confirms

Summary

A large study using VA health records found that getting a COVID vaccine and a flu shot on the same day does not increase the risk of adverse events compared to receiving a flu vaccine alone. Researchers examined 46 different potential side effects across over 2.5 million people and found no statistically significant increase in serious, clinically significant, or even mild adverse events with coadministration. The study spanned three COVID vaccine formulation eras from 2022 to 2025, making it more relevant to current vaccines than older pandemic-era safety data. The findings are particularly reassuring for older adults and those with chronic conditions, reinforcing that COVID vaccination still carries a favorable risk-benefit balance.

Detailed Summary

For health-conscious adults juggling annual vaccine schedules, a new large-scale study offers clear practical guidance: getting your COVID and flu shots on the same day is just as safe as getting the flu shot alone. Published in the Annals of Internal Medicine, the research analyzed electronic health records from the VA, covering more than 2.5 million people across three recent COVID vaccine formulation eras between September 2022 and August 2025.

The study used a target trial emulation design, comparing 705,124 people who received both vaccines on the same day against 1,813,205 who received only a flu shot. Importantly, the active-comparator design — matching two vaccinated groups rather than comparing vaccinated to unvaccinated — helped reduce healthy-vaccinee bias, strengthening the validity of the findings.

Researchers assessed 46 individual adverse events across three composite outcome categories: serious or life-threatening, clinically significant, and less severe or self-limiting. None reached statistical significance after correcting for multiple comparisons. Two outcomes showed nominal signals — a slight increase in syncope risk and a slight decrease in tinnitus risk — but neither held up under rigorous statistical correction. Myocarditis risks were small in both groups.

The study's timeframe is a key strength. Most widely cited vaccine safety data still derive from early pandemic vaccines administered to immunologically naive populations. This research reflects contemporary hybrid immunity — people who have had multiple vaccine doses and likely prior infection — offering more relevant safety reassurance for today's public.

Lead researcher Ziyad Al-Aly emphasized that despite declining COVID severity, the disease remains a real threat, especially for older adults and those with comorbidities. The risk-benefit balance still favors vaccination. Practically, coadministration saves time and may improve adherence to both vaccine recommendations, making it a sensible default for most adults.

Key Findings

  • Same-day COVID and flu coadministration showed no increased risk across 46 assessed adverse events in 2.5M+ people.
  • No statistically significant increase in myocarditis risk was found with coadministration versus flu vaccine alone.
  • Study spans 2022–2025, covering bivalent, XBB-adapted, and KP-adapted COVID vaccine formulations for modern relevance.
  • Active-comparator design comparing two vaccinated groups reduces healthy-vaccinee bias, strengthening safety conclusions.
  • Findings especially reassure older adults and those with comorbidities that COVID vaccination risk-benefit still favors vaccination.

Methodology

This is a news report summarizing a peer-reviewed target trial emulation published in the Annals of Internal Medicine, a high-credibility journal. The study used VA electronic health record data from over 2.5 million people, with an active-comparator design to reduce bias. Evidence quality is strong given the large sample size and multi-era vaccine coverage.

Study Limitations

The VA population is predominantly male (over 92%) and white, limiting generalizability to women and more diverse populations. The study is observational in design, even with emulation methodology, so unmeasured confounders cannot be fully excluded. Readers should consult the primary Annals of Internal Medicine publication for full statistical detail and outcome definitions.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: